Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 | Q09428 | 5/20 | 0.54 |
| ▸ | KCNJ11 | Q14654 | 5/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.36 |
| ▸ | GYS1 | P13807 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366923 | 0.83 | ALDH1A1 (0.40) | ABCC8KCNJ11HCAR2ALDH1A1MAPT | |
| SCHEMBL9912567 | 0.78 | ABCC8 (0.43) | ABCC8KCNJ11ALDH1A1MAPT | |
| SCHEMBL29517032 | 0.75 | ABCC8 (0.55) | ABCC8KCNJ11GYS1ALDH1A1MAPT | |
| SCHEMBL331274 | 0.75 | ALDH1A1 (0.36) | HCAR2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL4185273 | 0.74 | ALOX15 (0.44) | ABCC8KCNJ11HCAR2ALOX15 | |
| SCHEMBL1559276 | 0.74 | MAPT (0.53) | HCAR2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL3464362 | 0.74 | ABCC8 (0.54) | ABCC8KCNJ11GYS1ALDH1A1MAPT | |
| SCHEMBL570053 | 0.72 | HCAR2 (0.50) | HCAR2 | |
| SCHEMBL1558736 | 0.70 | HCAR2 (0.57) | HCAR2ALDH1A1MAPTCASP7CASP6 | |
| SCHEMBL6366922 | 0.70 | MAPT (0.36) | HCAR2ALDH1A1MAPTCASP7CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933095-B2 | KAT II inhibitors | PFIZER INC. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2646443-B1 | KAT II INHIBITORS | PFIZER (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2646443-B1 | KAT II INHIBITORS | PFIZER (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057938-A1 | KAT ll INHIBITORS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8598200-B2 | KAT II inhibitors | PFIZER INC. (US) | 2013-12-03 | — | — | US | disclosed |
| CN-103228660-A | Kat II inhibitors | PFIZER | 2013-07-31 | — | — | CN | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| US-20120302599-A1 | KAT ll INHIBITORS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073143-A1 | KAT II INHIBITORS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057938-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | ABCC8 3928/4885KCNJ11 1485/4885HCAR2 4053/4885 |
| US-20120302599-A1 | KAT ll INHIBITORS | KAT2A, KAT7, KAT5 | ABCC8 3928/4885KCNJ11 1485/4885HCAR2 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.